TARA

Rating neutralTentativeAI Memo

Protara Therapeutics

As of 2026-10-17/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-17 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

THRIVE-3 interim dose-confirmation results • 2026-12-31

Base target: $2 / p=50% prob

Biggest risk

The October enrollment announcement contains no interim efficacy result. Trial outcomes, timing and the planned 2027 BLA remain uncertain; a delayed milestone or weak safety, pharmacokinetic or durability data could outweigh the reported runway. [#IR-2026-10-15] Company release.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The newly completed THRIVE-3 dose-confirmation enrollment removes one execution step, while three distinct 4Q 2026 clinical or enrollment milestones could improve confidence in the pipeline. Protara reported approximately $162 million of cash, equivalents and investments at June 30 and expected funding into 2028. [#IR-2026-10-15] Company release; [#SEC-8K-2026-08-11] SEC-filed company release.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-17

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Planned TARA-002 lymphatic-malformations BLA
The newly completed THRIVE-3 dose-confirmation enrollment removes one execution step, while three distinct 4Q 2026 clinical or enrollment milestones could improve confidence in the pipeline.
Protara reported approximately $162 million of cash, equivalents and investments at June 30 and expected funding into 2028.

BearKey bullets

ADVANCED-2 enrollment timing and later efficacy or durability may disappoint; enrollment alone is not a clinical readout.
[#SEC-8K-2026-08-11]
ADVANCED-3 is being redesigned as an exploratory trial, creating protocol and timing uncertainty.

WatchKey bullets

THRIVE-3 interim dose-confirmation results

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=50%)

Target spread vs base: +67% / -50%

Scenario probabilities

Bull Target: $4 (p=20%)Base Target: $2 (p=50%)Bear Target: $1 (p=30%)

Commentary

Neutral, event-driven monitoring view. TARA closed at $2.32 on October 16, down from $2.40 on October 15, but the decline cannot be attributed solely to the enrollment release. Historical prices. The August AP earnings snapshot reported a $0.36-per-share Q2 loss versus a cited $0.33 consensus loss; it is not an official company release. AP report. No dependable current analyst revisions, options, short-interest or social measures were supplied; zero sentiment fields denote unavailable data, not measured neutrality.

As of 2026-10-17 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Planned TARA-002 lymphatic-malformations BLA

Scenarios

Bull Target (Scenario probability)

$4 / p=20% prob

Base Target (Scenario probability)

$2 / p=50% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Analysis 2026-10-17 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
THRIVE-3 interim dose-confirmation results
Protara completed enrollment of the 24-patient Phase 2b dose-confirmation cohort on October 15 and still expects interim results in 4Q 2026. Enrollment is achieved; the forthcoming safety and pharmacokinetic data remain the valuation-sensitive event. [#IR-2026-10-15] Company release.
Prob 70.00% • Move 20.00% • Priced-in 35.00%
EVENT2026-12-31
ADVANCED-2 registrational-cohort enrollment
Management expects to complete enrollment of the BCG-unresponsive NMIBC cohort in 4Q 2026. Completion would support execution confidence, but it would not establish efficacy. [#8-K-2026-08-11] [#SEC-8K-2026-08-11] SEC-filed company release.
Prob 65.00% • Move 15.00% • Priced-in 45.00%
EVENT2026-12-31
STARBORN-1 update and enrollment completion
Protara expects a lymphatic-malformations trial update and enrollment completion in 4Q 2026. Durability, safety and regulatory-path details matter more than enrollment alone. [#SEC-8K-2026-08-11] SEC-filed company release.
Prob 60.00% • Move 22.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Planned TARA-002 lymphatic-malformations BLA
2027-12-31
Following FDA discussions, Protara intends to submit a biologics license application in 2H 2027 based on STARBORN-1. Submission remains contingent on the trial and regulatory work; approval is not implied. [#SEC-8K-2026-08-11] SEC-filed company release.
Prob 50% • Move 25% • Priced-in 25%

Risks

ADVANCED-2 enrollment timing and later efficacy or durability may disappoint; enrollment alone is not a clinical readout. [#SEC-8K-2026-08-11]
ADVANCED-3 is being redesigned as an exploratory trial, creating protocol and timing uncertainty. [#SEC-8K-2026-08-11]
Clinical spending could reduce the June 30 cash balance; the company's runway estimate is forward-looking. [#SEC-8K-2026-08-11]
STARBORN-1 data and FDA interactions may not support the intended second-half 2027 BLA timetable. [#SEC-8K-2026-08-11]
THRIVE-3 Phase 2b enrollment is complete, but interim safety and pharmacokinetic results and subsequent Phase 3 execution remain unproven. [#IR-2026-10-15]

Peers

Symbol	Summary
ADAG	Same-sector, similar-market-cap candidate only; its pipeline is not established here as a direct TARA-002 or IV Choline Chloride comparable. Do not infer a valuation multiple from it.
MSLE	Similar-market-cap biotechnology candidate, but program, stage and financing comparability are unverified. Useful only as a broad event-risk reference.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-17

Loading AI feed…

Symbol

Summary

ADAG

Same-sector, similar-market-cap candidate only; its pipeline is not established here as a direct TARA-002 or IV Choline Chloride comparable. Do not infer a valuation multiple from it.

MSLE

Similar-market-cap biotechnology candidate, but program, stage and financing comparability are unverified. Useful only as a broad event-risk reference.